A smart beta exchange traded fund, the State Street SPDR S&P Pharmaceuticals ETF (XPH) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market.What Are Smart Beta ETFs?Products that are based on market cap weighted indexes, which are strategies designed to reflect a specific market segment or the market as a whole, have traditionally dominated the ETF industry.Because market cap weighted indexes provide a low-cost, convenient, and transparent way of replicating market ...

It's not only tech companies that can get to that market valuation.No healthcare company has ever achieved the remarkable feat of a $1 trillion market capitalization. At least that was true until Nov. 21, when Eli Lilly (LLY 0.51%), a pharmaceutical giant, became the first in the industry to get there.And the best news is that it likely still has plenty of upside potential. Given its current momentum, Eli Lilly could even hit $2 trillion by 2031. The company needs a compound annual growth rate of 12.3% to a ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 27, 2025 /PRNewswire/ -- Details of the case: According to the lawsuit, James Hardie Industries plc misled investors about the strength of its key North America Fiber Cement segment between May 20 and August 18, 2025. Despite knowing by April and early May that distributors were destocking inventory, James Hardie falsely claimed demand remained strong and that stock levels were "normal." When the true details entered the market, the lawsuit claims that i ...

We recently published 10 Big Names Feasting on Gains Ahead of Thanksgiving. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the best-performing stocks on Wednesday. Arrowhead Pharmaceuticals soared to a new three-year high on Wednesday, as investors took heart from its impressive earnings performance for the full fiscal year, alongside the Food and Drug Administration’s (FDA) approval for its treatment for familial chylomicronemia syndrome (FCS). At intra-day trading, the stock soared to as high ...

Dividends can help enrich your portfolio for years to come.Dividend stocks can provide a source of regular cash flow to your portfolio that can be reinvested to buy more shares or used as income. Whether you're a brand new investor or are closer to retirement, dividend stocks can certainly have a place in your portfolio.Companies that pay consistent dividends are often well-established and financially stable, which can provide some cushion during market downturns. If you're looking for three dividend stocks ...

南财智讯11月27日电，步长制药公告，全资子公司陕西步长取得陕西省药品监督管理局换发的《药品生 产许可证》，同意《药品生产许可证》的变更申请。发证机关为陕西省药品监督管理局。变更事项详 情：同意企业在陕西省咸阳市秦都区步长路16号地址双氯胶囊车间新增片剂生产线；磷酸西格列汀片 （仅用于产品注册）由受托山东丹红制药有限公司生产变更为自行生产，通过GMP符合性检查。对生 产经营的影响：本次变更有利于公司优化生产结构，有利于继续保持稳定的生产能力，满足市场需求， 对公司的未来经营产生积极影响。许可证编号：陕20160035。 ...

Core Insights - Bristol Myers Squibb (BMY) received European Commission approval for Breyanzi, expanding its label to include treatment for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor [1][9] Group 1: Breyanzi Approval and Indications - The latest approval marks the fourth for Breyanzi in Europe, which is already approved for several other indications including relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBCL) [2] - Breyanzi is indicated for patients who relapsed within 12 months of first-line chemoimmunotherapy or are refractory to it, as well as for those with relapsed or refractory DLBCL, PMBCL, and FL3B after two or more lines of therapy [3] Group 2: Clinical Trial Results - The approval is based on the TRANSCEND NHL 001 trial results, where 82.7% of patients responded to Breyanzi, with 71.6% achieving a complete response, and 41.2% of patients maintained their response at 24 months [4][9] Group 3: Pipeline Expansion and Market Impact - Bristol Myers is focusing on expanding its pipeline due to the negative impact of generics on its legacy portfolio, including Revlimid and Pomalyst [5] - The company’s shares gained 3.3% following positive data from Bayer's cardiovascular candidate asundexian, which may boost investor confidence in BMY's own cardiovascular candidate, milvexian [6][8] Group 4: Discontinuation of Librexia Study - Bristol Myers and Johnson & Johnson decided to discontinue the late-stage Librexia study for milvexian after an interim analysis indicated it was unlikely to meet primary efficacy endpoints, although two other studies for milvexian will continue [10][11]

These top dividend stocks could intrigue a wide range of investors.Dividend stocks can be a profitable component of a long-term investor's portfolio. Because their payouts provide a fairly reliable flow of cash, such stocks can be particularly appealing for retirees or others seeking passive income that will enable them to meet their liquidity needs without selling shares. When reinvested, dividends can contribute significantly to your total returns over time. Shares of companies that pay consistent dividen ...

Core Insights - Gan & Lee Pharmaceuticals has initiated the GRADUAL-3 phase 3 clinical study for its GLP-1 receptor agonist, bofanglutide, targeting adults with obesity or overweight [1][3] - The study aims to evaluate the efficacy and safety of once-monthly bofanglutide injection over a 24-week period [2][7] - Previous studies, GRADUAL-1 and GRADUAL-2, have established the groundwork for assessing bofanglutide's effectiveness in weight management [3][7] Study Design and Objectives - GRADUAL-3 is designed to explore the potential of bofanglutide to maintain weight loss and improve long-term adherence by administering the injection subcutaneously once every four weeks [1][4] - The primary endpoints of the study include changes in body weight and percentage change from baseline at Week 24 [2][7] - The study is part of a broader GRADUAL clinical development program, which includes three large-scale phase 3 studies with over 1,000 participants planned for enrollment [4] Previous Clinical Studies - GRADUAL-1 involved approximately 630 Chinese adults and assessed the weight-loss efficacy and safety of bofanglutide over 52 weeks [7] - GRADUAL-2 included around 471 participants and compared bofanglutide with semaglutide (Wegovy) in a head-to-head study [3][7] - Both previous studies aimed to confirm the efficacy and safety of bofanglutide in managing obesity and its impact on metabolic parameters [3][5] Product Overview - Bofanglutide (research code: GZR18) is a novel GLP-1 RA developed by Gan & Lee, focusing on obesity/overweight and type 2 diabetes indications [5] - Clinical studies have shown that bofanglutide provides significant weight-loss and glucose-lowering effects, with a safety profile consistent with existing GLP-1 RAs [5]

Chugai's Value Creation & Sustainability - Chugai reorganized its value creation process in 2024, using materiality as axes, aiming to realize advanced and sustainable patient-centric healthcare[9] - The company focuses on creating innovative drugs and services, providing individualized solutions, ensuring quality, and co-creating a healthcare ecosystem[12] - Chugai is implementing materiality by aligning business activities with its materiality story, reflected in management strategies and division activities[14, 16, 20] - A project using the antibody drug discovery support technology MALEXA has advanced to clinical development stage[22, 23] - The company is constructing a disease database for blood coagulation disorders in cooperation with patient associations and academia[29, 35] - Chugai achieved 100% renewable energy ratio in purchased electricity[39] Mid-Size Molecule Drug Platform - Chugai is establishing a pharmaceutical technology platform for mid-size molecule drugs to provide new treatment options[6, 52] - The company is developing a new liquid-phase synthesis method to improve the efficiency of producing mid-size molecules[65] - Through joint research, the cost of certain non-natural amino acids was reduced to less than one third[77] - A 55.5 billion yen investment was made in Fujieda in 2024, 128.8 billion yen in Yokohama in 2022, and 4.5 billion yen in Ukima in 2020[90] Governance and Shareholder Value - Chugai emphasizes dialogue with investors to enhance governance and increase shareholder value[120] - Non-executive directors play a key role in monitoring and advising on management from a global perspective[129] - The company's average annual Total Shareholder Return (TSR) for the past 10 years is 23.5%, compared to 9.5% for TOPIX and 7.8% for TOPIX-17 Pharmaceutical Index[150]